These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23419484)

  • 1. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
    Drenberg CD; Baker SD; Sparreboom A
    Clin Pharmacol Ther; 2013 Mar; 93(3):215-9. PubMed ID: 23419484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors in pediatric malignancies.
    Skolnik JM; Adamson PC
    Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
    Carmi C; Mor M; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
    Slobbe P; Poot AJ; Windhorst AD; van Dongen GA
    Drug Discov Today; 2012 Nov; 17(21-22):1175-87. PubMed ID: 22766374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    Mikalsen T; Gerits N; Moens U
    Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors in veterinary medicine.
    London CA
    Top Companion Anim Med; 2009 Aug; 24(3):106-12. PubMed ID: 19732728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Playing Russian roulette with tyrosine kinase inhibitors.
    Szmulewitz RZ; Ratain MJ
    Clin Pharmacol Ther; 2013 Mar; 93(3):242-4. PubMed ID: 23340477
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
    Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
    Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.